Latest from Incanthera

Directors dealings

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the “Transactions”).

The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:

EmployeeCompany PositionTransaction VolumePurchase Price
Tim McCarthy Chairman 49,382 13.50p
Simon Ward CEO 51,593 13.50p
Pawel Zolnierzyck COO 11,307 13.20p
Laura Brogden CFO 15,057 13.15p
Suzanne Brocks Head of Communications 50,000 13.00p

Total Shareholdings following the Transactions:

EmployeeCompany PositionTotal Shareholding% of Share Capital 
Tim McCarthy Chairman 3,931,646 5.31%
Simon Ward CEO 2,704,199 3.65%
Pawel Zolnierzyck COO 669,544 3.65%
Laura Brogden CFO 46,034 0.06%
Suzanne Brocks Head of Communications 325,594 0.44%


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

For further enquiries:

Incanthera plc

Tim McCarthy, Chairman
+44 (0) 7831 675747

Simon Ward, Chief Executive Officer
+44 (0) 7747 625506

Suzanne Brocks, Head of Communications
+44 (0) 7776 234600

Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers
+44 (0) 20 7213 0880

Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney
+44 (0) 20 3815 8880

Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: